Adherence to pharmacotherapy for secondary prevention of coronary heart disease: A registry-based prospective study

Simple item page
dc.contributor.authorBana, Aradhaien_US
dc.contributor.authorSharma, Krishna Kumaren_US
dc.contributor.authorGuptha, Soneilen_US
dc.contributor.authorGupta, Rajeeven_US
dc.date.accessioned2025-08-13T11:15:22Z
dc.date.available2025-08-13T11:15:22Z
dc.date.issued2025-04
dc.description.abstractBackground and objective: There is limited data on secondary prevention medications following acute coronary syndrome (ACS) in India. We performed a registry-based study to evaluate adherence to recommended medi- cations following ACS hospitalisation. Methods: Consecutive patients admitted with ACS were recruited. Data on demographics, baseline characteristics, in-hospital interventions, and prescribed secondary prevention therapies (antiplatelets, statins, beta-blockers, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB) at discharge were recorded. 6-months follow-up was conducted to evaluate adherence using validated tools. Results: 716 patients were recruited; the mean age was 60.4 ± 11 years, percutaneous coronary angioplasty (PCI) was performed in 714 (99.7 %) and bypass surgery in none. At hospital discharge, the cardioprotective medi- cations were: aspirin 97.3 %, dual antiplatelets 99.7 %, statins 99.7 %, beta-blockers 74.2 %, ACEI/ARB 38.8 % and CCB 10.9 %. Follow-up data were available for 554 patients; 15 (2.1 %) died and 147 (20.5 %) were lost to follow-up. Medication status and change at 6 months was aspirin 83.9 % ( 15.9 %); dual antiplatelets 70.2 % ( 29.5 %), statins 70.0 % ( 29.8 %), beta-blockers 50.4 % ( 32.1 %), ACEI/ARB 22.4 % ( 42.3 %) and CCB ( 36.7 %) (p < 0.05). Use of high-intensity statins declined from 92.0 % to 45.7 % ( 50.3 %). At follow-up, good adherence (>80 %) was 42.7 %, low adherence 24.4 % and non-adherence 10.2 %. Patients with government- sponsored insurance had better adherence than privately insured and self-paying. Conclusions: Following acute coronary syndrome and PCI, the adherence to prescribed pharmacotherapy is sub- optimal at 6 months with a decline in various medications of 16–42 %. Strategies to increase adherence to secondary prevention therapies are required.en_US
dc.identifier.affiliationsNorwich Medical School, University of East Anglia, Norwich, NR47TJ, UKen_US
dc.identifier.affiliationsDepartment of Pharmacology, Lal Bahadur Shastri College of Pharmacy, Rajasthan University of Health Sciences, Jaipur, 302004, Indiaen_US
dc.identifier.affiliationsPrimary Care, Rocky Vista University, Ivins, UT, 84738, USAen_US
dc.identifier.affiliationsDepartment of Preventive Cardiology, Eternal Heart Care Centre & Research Institute, Jaipur, 302017, Indiaen_US
dc.identifier.citationBana Aradhai, Sharma Krishna Kumar, Guptha Soneil, Gupta Rajeev. Adherence to pharmacotherapy for secondary prevention of coronary heart disease: A registry-based prospective study. Indian Heart Journal. 2025 Apr; 77(2): 84-88en_US
dc.identifier.issn0019-4832
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/253349
dc.languageenen_US
dc.publisherElsevieren_US
dc.relation.issuenumber2en_US
dc.relation.volume77en_US
dc.source.urihttps://doi.org/10.1016/j.ihj.2025.02.009en_US
dc.subjectAcute coronary syndromeen_US
dc.subjectAdherenceen_US
dc.subjectAntiplateletsen_US
dc.subjectStatinsen_US
dc.subjectSecondary preventionen_US
dc.titleAdherence to pharmacotherapy for secondary prevention of coronary heart disease: A registry-based prospective studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ihj2025v77n2p84.pdf
Size:
818.67 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Heart Journal